Social Media Ideas for 340B Drug Discount Program

The 340B Squeeze: Academic Medical Centers and Large Health Systems Have the Most to Lose

Three federal pricing changes are about to land on a single outpatient claim. The largest infusion and oncology programs will feel them first, and hardest. Most of the 340B debate...

HHS: 340B 'expanded beyond its original intent,' incentivizes consolidation

A new brief lays out the administration's views and critiques of the controversial hospital subsidy program, and includes a data analysis suggesting that a proposed reimbursement c...

HRSA names 10 drugmakers for revised 340B rebate pilot ahead of 2027 launch

The list of approved participants and drugs is larger than the controversial pilot's first attempted launch. It comes the same day that CMS launched a soon-to-be-mandatory data rep...

<![CDATA[340B Under Pressure: Inside Pharma's Push for Greater Clarity]]>

This Week in 340B- August 25 – 31, 2026

340B Rebate Pilot — The Clock Starts Now

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

Froedtert sues CVS over $18M in 340B drug discounts

Froedtert Hospital is suing CVS Health, alleging CVS improperly kept $18 million in reimbursements from the federal 340B drug discount program. The post Froedtert sues CVS over $18...

This Week in 340B: August 18 – 24, 2026

This Week in 340B: October 13 – 19, 2026

This Week in 340B—September 22 – 28, 2026

This Week in 340B: October 6 – 12, 2026

This Week in 340B: September 8 – 14, 2026

This Week in 340B: September 1 – 7, 2026

Mid-cap biotechs join Trump’s latest round of drug pricing deals

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

Drugstores say Medicare's $50 obesity drug program is catching on

The Bridge program, which began July 1, makes some Medicare beneficiaries eligible for obesity drugs for $50 a month. CVS and Walgreens say they've each already filled 100,000 such...

Drug Channels News Roundup, September 2026: The 340B Margin Squeeze, Economics of Cutting List Price, Patient Adherence...

By Bryce Platt, PharmD Football season is officially back. Personally, my signal is hearing my uncle curse about bad calls from 1,000 miles away, but you may have already seen...

Medicare's pilot GLP-1 discount program has a catch. Some sick patients don't qualify

Medicare launched a pilot program that could streamline the process to get GLP-1s, with some seniors paying just $50 a month. But many people with the most serious illnesses won't...

Medicaid Favored Pricing

Prescription drug prices have now recorded their sharpest annual drop in more than 60 years — and those lower prices now reach every Medicaid program in America.

Hospital industry sues to block HHS' 340B rebate pilot (again)

The American Hospital Association and others have launched a legal rematch with the federal government over the second iteration of a pilot program swapping out safety-net hospital...

This Week in 340B: September 15 – 21, 2026

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 3...

This Week in 340B: September 29 – October 5, 2026

Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 3...

The Private Label Biosimilar Paradox in Medicare Part D

By Tyler Novotny and Bryce Platt PBM-affiliated private label biosimilars would seem to have a built-in formulary advantage. But for ustekinumab, that advantage has not carrie...

The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don't Qualify

WEDNESDAY, Aug. 26, 2026 — In January, Jeff La Marca got a prescription for the popular weight loss drug Zepbound. But he couldn’t afford the $750 monthly price tag. “I thought, ‘T...